SIGMA HEALTHCARE LIMITED (SIG)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SIG

SIG - SIGMA HEALTHCARE LIMITED

FNArena Sector : Health & Nutrition
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 1.04
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$3.01

02 Oct
2025

0.040

OPEN

$2.99

1.35%

HIGH

$3.04

28,719,620

LOW

$2.98

TARGET
$3.057 1.6% upside
Franking for last dividend paid out: 50%
OTHER COMPANIES IN THE SAME SECTOR
CLV . EBO . EXL . MCP .
FNARENA'S MARKET CONSENSUS FORECASTS
SIG: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 5.1 6.2 xxx
DPS (cps) xxx 1.8 3.9 xxx
EPS Growth xxx 100.0% 22.9% xxx
DPS Growth xxx 82.7% 100.0% xxx
PE Ratio xxx N/A 48.1 xxx
Dividend Yield xxx N/A 1.3% xxx
Div Pay Ratio(%) xxx 35.6% 62.1% xxx

Dividend yield today if purchased 3 years ago: 2.65%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.60

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 28/03 - ex-div 0.5c (franking 50%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx5.1
DPS All xxxxxxxxxxxxxxx1.8
Sales/Revenue xxxxxxxxxxxxxxx14,404.4 M
Book Value Per Share xxxxxxxxxxxxxxx40.6
Net Operating Cash Flow xxxxxxxxxxxxxxx598.8 M
Net Profit Margin xxxxxxxxxxxxxxx8.83 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-
Return on Invested Capital xxxxxxxxxxxxxxx-
Return on Assets xxxxxxxxxxxxxxx-
Return on Equity xxxxxxxxxxxxxxx-
Return on Total Capital xxxxxxxxxxxxxxx-
Free Cash Flow ex dividends xxxxxxxxxxxxxxx60.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx194 M
Long Term Debt xxxxxxxxxxxxxxx1,877 M
Total Debt xxxxxxxxxxxxxxx2,071 M
Goodwill - Gross xxxxxxxxxxxxxxx3,617 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx139 M
Price To Book Value xxxxxxxxxxxxxxx7.36

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx57.6 M
Capex % of Sales xxxxxxxxxxxxxxx0.40 %
Cost of Goods Sold xxxxxxxxxxxxxxx10,948 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx1,606 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx80 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.2

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

xx/xx/xxxx

3

xxxxxxx xx xxxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

2

xxxxxxx xx xxxxxxxxxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

28/08/2025

5

Underperform

$2.50

-16.94%

Sigma Healthcare released FY25 results accounting for the reverse acquisition of Sigma by Chemist Warehouse, effective in February. Top-line growth remains robust, Macquarie notes, with momentum continuing in FY26.

Chemist Warehouse sales are growing double digits year on year. Sigma earnings are expected to double between 2025-28 as the company exploits organic and international growth opportunities.

Sigma continues to deliver on its growth strategy, with a market-leading offer, and strong execution across the top-line and bottom-line. However, at a one-year forward PE of 48x, Macquarie sees valuation as stretched.

Underperform retained, target falls to $2.50 from $2.60.

FORECAST
Macquarie forecasts a full year FY26 dividend of 3.80 cents and EPS of 6.30 cents.
Macquarie forecasts a full year FY27 dividend of 4.80 cents and EPS of 8.00 cents.

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

12/09/2025

2

Overweight

$3.40

12.96%

In an ongoing research deep dive on Sigma Healthcare, Jarden suggests Chemist Warehouse is well placed for global expansion, with a $330bn market opportunity across Ireland, the UK, Middle East and North Africa (MENA) and Europe.

The broker values offshore at 63c a share (19% of the unchanged $3.40 target) but notes potential to exceed $6.00 if Chemist Warehouse reaches 3% share, or around 2,800 stores, generating $10.4bn in sales.

Early success in Ireland and the UAE supports the model, with stores priced -29–33% below rivals. The UK offers a large $83bn total addressable market (TAM) and lacks a discounter model, highlight the analysts.

The MENA region also provides strong growth drivers, according to Jarden. Spain and Italy present nearer-term opportunities in Europe, with Germany and France longer dated.

 Jarden retains an Overweight rating.

FORECAST
Jarden forecasts a full year FY26 dividend of 3.60 cents and EPS of 6.00 cents.
Jarden forecasts a full year FY27 dividend of 4.30 cents and EPS of 7.20 cents.
Access Extra Coverage Research History >

SIG STOCK CHART

FNArena News on SIG

Latest Health & Nutrition News

1
Sigma Healthcare: Brokers Wary

Mar 31 2022 - Australia
2
Health & Wellness Boom On The ASX

Apr 29 2021 - Weekly Reports
3
M&A Now On Sigma Healthcare’s Agenda

Mar 24 2021 - Australia
4
McPherson’s Expands Into Herbal Health

Nov 04 2020 - Small Caps
5
Nine Ignored Companies Now Worth A Look

Sep 23 2020 - FYI
6
Next Week At A Glance – 14-18 Sep 2020

Sep 11 2020 - Weekly Reports
7
Sigma Farewells API, Heralds New Contract

Dec 17 2019 - Australia
8
Blackmores: Hopes Pinned On Restructuring

Nov 01 2019 - Australia
9
Blackmores Peps Up Its Strategy For China

Apr 17 2019 - Australia
10
API/Sigma Merger Plan Rears, Again

Dec 17 2018 - Australia